Certificata UNI EN ISO 9001:2015
53
rdAISF Virtual Annual Meeting
March 3rd-4th-5th, 2021
S
C I E N T I F I CP
R O G R A M M EWednesday, March 3
rd14.25-14.30 Introduction - Salvatore Petta, Palermo
14.30-15.00 State-of-the-Art Lecture
Immunopathogenesis of hepatitis B: from infection to liver cancer - Luca Guidotti, Milan Introduced by: Giovanni Raimondo, Messina
15.00-15.50 Selected Oral Communications on Viral Hepatitis
Chairpersons: Salvatore Petta, Palermo - Alessio Aghemo, Rozzano (MI) - Mario Masarone, Salerno - Sara Montagnese, Padua - Francesca Romana Ponziani, Rome - Francesco Paolo Russo, Padua
Changing demographic-clinic-pathologic profiles of newly diagnosed carriers of chronic hepatitis B virus infection across two decades: a single regional reference center report Presenter: G. Ricco, Pisa
(Abstract Authors: G. Ricco, P. Bleve, B. Coco, D. Cavallone, P. Colombatto, F. Oliveri, V.
Romagnoli, A. Salvati, F. Bonino, M.R. Brunetto – Pisa)
Long-term effective oral therapy could spare endoscopic surveillance of esophageal varices in HBV compensated cirrhotics: a 10-year study
Presenter: E. Farina, Milan
(Abstract Authors: E. Farina, A. Loglio, G. Tosetti, M. Viganò, C. Gentile, R. Perbellini, M. Borghi, F. Facchetti, SC. Uceda Renteria, MG. Rumi, M. Primignani, P. Lampertico – Milan)
A single center, large long-term cohort study of the relations between mutations in Basic- Core-Promoter and pre-C regions of Hepatitis B virus DNA and clinic-pathologic outcome of HBeAg-negative/anti-HBe-positive phase
Presenter: D. Cavallone, Pisa
(Abstract Authors: D. Cavallone, G. Ricco, D. Flichman, F. Moriconi, P. Colombatto, P. Bleve, B.
Coco, F. Oliveri, V. Romagnoli, A. Salvati, F. Bonino, M.R. Brunetto – Pisa, Buenos Aires- Argentina)
Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy:
the “Casola di Napoli” cohort study Presenter: M. Masarone, Salerno
(Abstract Authors: C. Coppola, M. Masarone, M. Bartoli, L. Staiano, P. Torre, M. Conforti, D. Amoruso, I. Gardini, M. Persico - Naples, Salerno, Rome)
Certificata UNI EN ISO 9001:2015
15.50÷16.50 Symposium: Lifestyle and the Liver
Chairpersons: Carmelina Loguercio, Naples - Giulio Marchesini Reggiani, Bologna 15.50-16.00 Diet and liver diseases - Manuela Merli, Rome
16.00-16.10 Physical Activity and liver diseases – Alessandro Federico, Naples 16.10-16.20 How to motivate lifestyle change? Luca Buffa, Imperia
16.20-16.30 Technology and eHealth support - Maria Letizia Petroni, Bologna 16.30-16.50 Discussion
16.50-17.40 Selected Oral Communications on NAFLD/NASH
Chairpersons: Salvatore Petta, Palermo - Alessio Aghemo, Rozzano (MI) - Mario Masarone, Salerno - Sara Montagnese, Padua - Francesca Romana Ponziani, Rome - Francesco Paolo Russo, Padua
SIRT5 rs12216101 T>G variant is associated with fibrosis severity in patients with non- alcoholic fatty liver disease
Presenter: F. Salomone, Catania
(Abstract Authors: F. Salomone, S. Grimaudo, F. Malvestiti, R.M. Pipitone, A. Distefano, G.
Baselli, G. Pennisi, P. Dongiovanni, A.L. Fracanzani, G. Li Volti, A. Craxì, S. Romeo, L. Valenti, S.
Petta - Catania, Palermo, Milan, Gothenburg-Sweden)
GEMS, a GEnetic and Metabolic Staging predicting the outcome of non-alcoholic fatty liver disease
Presenter: G. Pennisi, Palermo
(Abstract Authors: G. Pennisi, R. M. Pipitone, M. Enea, S. Battaglia, V. Di Marco, V. Di Martino, F. Spatola, R. Zito, C. Cammà, A. Craxì, S. Grimaudo, S. Petta – Palermo)
Metabolic alterations and hepatic fibrosis impact on severity of SARS-COV2 infection Presenter: R. Lombardi, Milan
(Abstract Authors: R. Lombardi, A. Cespiati, V. La Mura, F. Iuculano, G. Sigon, G. Pallini, M.
Proietti, I. Motta, B. Montinaro, E. Fiorelli, M. Cesari, F. Peyvandi, N. Montano, M. Baldini, A.L.
Fracanzani – Milan)
Definition of healthy ranges for alanine aminotransferase levels: a 2020 update Presenter: C. Bianco, Milan
(Abstract Authors: L. Valenti, S. Pelusi, C. Bianco, F. Ceriotti, A. Berzuini, L. Iogna Prat, R. Trotti, G. Baselli, R. D’Ambrosio, M. Colombo, E. Tsochatzis, M. Fraquelli, D. Prati – Milan, Udine, London-UK)
17.40-18.15 General Assembly I
18.15-18.45 Up to date Lecture on Specific Topics [No ECM]
Introduced by: Gloria Taliani, Rome 8 weeks to eliminate HCV
Loreta Kondili, Rome - Erica Villa, Modena 18.45-19.15 Up to date Lecture on Specific Topics [No ECM]
Chairperson: Pierluigi Toniutto, Udine
Patient-Centered Hepatitis C Virus care: for the entire HCV patient spectrum Alessia Ciancio, Turin
Certificata UNI EN ISO 9001:2015
Thursday, March 4
th14.30-15.00 State-of-the-Art Lecture
Disease Modifying Agents in Advanced Chronic Liver Diseases - Paolo Caraceni, Bologna Introduced by: Paolo Angeli, Padua
15.00-15.50 Selected Oral Communications on Autoimmune & Biliary Diseases/Miscellaneous
Chairpersons: Salvatore Petta, Palermo - Alessio Aghemo, Rozzano (MI) - Mario Masarone, Salerno - Sara Montagnese, Padua - Francesca Romana Ponziani, Rome - Francesco Paolo Russo, Padua
Clustering Reveals the Prognostic Role of Serum Albumin Values Within the Normal Range in Patients with Primary Biliary Cholangitis
Presenter: A. Gerussi, Monza
(Abstract Authors: A. Gerussi, D. Verda, D.P. Bernasconi, M. Carbone, A. Komori, M. Abe, M.
Inao, T. Namisaki, S. Mochida, H. Yoshiji, G. Hirschfield, K. Lindor, A. Pares, C. Corpechot, N.
Cazzagon, A. Floreani, M. Marzioni, D. Alvaro, U. Vespasiani-Gentilucci, L. Cristoferi, M.G.
Valsecchi, M. Muselli3, the Japan PBC Study Group, the Global PBC Study Group and the Italian PBC study group, B. E. Hansen, A. Tanaka, P. Invernizzi - Monza, Newton-MA, USA, Nagasaki-Japan, Ehime-Japan, Saitama-Japan, Nara-Japan, Toronto-Canada, Phoenix-AZ-USA, Barcelona-Spain, Paris-France, Padua, Ancona, Rome, Genova, Teikyo-Japan)
Outcomes and risk factors for recurrence of disease in adult liver transplantation due to Primary Sclerosing Cholangitis: a single-centre experience
Presenter: G. Vitale, Bologna
(Abstract Authors: G. Vitale, F. Odaldi, M.F. Conti, M. Serenari, F.G. Foschi, M.C. Morelli, A.
Siniscalchi, M. Ravaioli, M. Cescon – Bologna, Faenza-RA)
Ferroptosis in intrahepatic cholangiocarcinoma: an immunohistochemical study Presenter: S. Sarcognato, Treviso
(Abstract Authors: D. Sacchi, S. Sarcognato, L. Fabris, G. Zanus, E. Gringeri, M. Niero, M. Guido Treviso, Padua)
Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells
Presenter: A. Gentilini, Florence
(Abstract Authors: A. Gentilini, G. Lori, A. Caligiuri, C. Raggi, G. Di Maira, M. Pastore, B.
Piombanti, T. Lottini, A. Arcangeli, S. Madiai, A. Taddei, J.M. Banales, S. Di Matteo, D.
Alvaro, J.B. Andersen, L. Duwe, A. Tubita, E. Rovida, F. Marra - Florence, San Sebastian-Spain, Rome, Copenhagen-Denmark)
15.50÷16.50 Rare Liver diseases Symposium
Chairpersons: Ana Lleo De Nalda, Rozzano (MI) - Luca Valenti, Milan
15.50-16.05 Novel therapeutic approaches in cholestatic autoimmune disorders: evidence from clinical studies
Pietro Invernizzi, Milan
16.05-16.20 An update on the diagnosis, natural history and clinical management of Gaucher disease Fabio Nascimbeni, Modena
16.20-16.35 Unusual hepatic presentations of rare genetic disorders Serena Pelusi, Milan
16.35-16.50 Discussion
Certificata UNI EN ISO 9001:2015
16.50-17.40 Selected Oral Communications on Clinical and Experimental Fibrosis and Cirrhosis Chairpersons: Salvatore Petta, Palermo - Alessio Aghemo, Rozzano (MI) - Mario Masarone, Salerno - Sara Montagnese, Padua - Francesca Romana Ponziani, Rome - Francesco Paolo Russo, Padua
RESIST-HCV criteria are able to rule out esophageal varices progression in patients with HCV cirrhosis treated by Direct-acting Antiviral Agents (DAAs)
Presenter: V. Calvaruso, Palermo
(Abstract Authors: V. Calvaruso, S. Petta, M. Licata, F. Simone, L. Di Marco, L. Crapanzano, C.
Cammà, A. Craxì, V. Di Marco – Palermo)
Clinical, neuropsychological and neurophysiological indices and predictors of hepatic encephalopathy (HE)
Presenter: L. Zarantonello, Padua
(Abstract Authors: C. Formentin, L. Zarantonello, C. Mangini, A. C. Frigo, S. Montagnese, C.
Merkel – Padua)
General Practitioner databaSe NAFLD (GPS-NAFLD) Study: prevalence of advanced liver fibrosis among Italian primary care patients with NAFLD
Presenter: L. Miele, Rome
(Abstract Authors: L. Miele, C. Cricelli, F. Lapi, I. Grattagliano, M. Dajko, A. Liguori, A. De Magistris, C. Napodano, A. Rossi, G.L. Rapaccini, A. Gasbarrini, A. Grieco – Rome, Florence) Preventing hepatic fibrogenesis with the two extra-virgin olive oil polyphenols tyrosol and hydroxytyrosol via NOX inhibition
Presenter: D. Gabbia, Padua
(Abstract Authors: D. Gabbia, S. Carpi, S. Sarcognato, M. Colognesi, B. Polini, M. Digiacomo, C.
Manera, J.E. Salsano, M. Macchia, P. Nieri, P. Invernizzi, F.P. Russo, A. Floreani, N. Cazzagon, M. Guido, S. De Martin – Padua, Pisa, Monza)
17.40-18.10 «Valerio Nobili» Young Investigator Lecture Cholestatic Liver Diseases - Marco Carbone, Milan Introduced by: Pietro Invernizzi, Milan
18.10-19.10 Up to date Symposium on Specific Topics [No ECM]
Introduced by: Fabio Piscaglia, Bologna Lenvatinib in HCC: evidence that matters
Sherrie Bhoori, Milan - Giovan Giuseppe Di Costanzo, Naples - Fabio Piscaglia, Bologna
Certificata UNI EN ISO 9001:2015
Friday, March 5
th14.30-15.00 State-of-the-Art Lecture
Liquid biopsy: next generation biomarkers for liver cancer Jesus M. Banales, Navarra - Spain
Introduced by: Domenico Alvaro, Rome
15.00-15.50 Selected Oral Communications on Hepatocellular Carcinoma
Chairpersons: Salvatore Petta, Palermo - Alessio Aghemo, Rozzano (MI) - Mario Masarone, Salerno - Sara Montagnese, Padua - Francesca Romana Ponziani, Rome - Francesco Paolo Russo, Padua
Complete response after biological downstaging in patients with hepatocellular carcinoma:
XXL-like prioritization for liver transplantation or awaiting and see strategy?
Presenter: F. Scolari, Padua
(Abstract Authors: F. Scolari, A. Bertacco, A. Vitale, P. Angeli, P. Burra, U. Cillo – Padua) Pattern of macrovascular invasion in patients with hepatocellular carcinoma influences treatment and outcome
Presenter: M. Guarino, Naples
(Abstract Authors: M. Guarino, A. Cucchetti, G. Pontillo, F. Farinati, F. Benevento, G.L.
Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, R. Sacco, G. Cabibbo, F. Marra, A. Mega, A.
Gasbarrini, G. Svegliati-Baroni, F.G. Foschi, G. Missale, A. Masotto, G. Nardone, G. Raimondo, F. Azzaroli, G. Vidili, F. Oliveri, F. Trevisani, E.G. Giannini, F. Morisco for the ITA.LI.CA Group – Naples, Forlì, Bologna, Padua, Rome, Seriate (BG), Viterbo, Foggia, Palermo, Florence, Bolzano, Ancona, Faenza-RA, Parma, Negrar-VR, Messina, Sassari, Pisa, Genova)
Impact of hospital volume on hepatocellular carcinoma survival in Italy Presenter: F. Pelizzaro, Padua
(Abstract Authors: F. Pelizzaro, A. Imondi, A. Sartori, B. Penzo, A. Vitale, F. Trevisani, F. Farinati on behalf of the Italian Liver Cancer (ITA.LI.CA) group – Padua, Bologna)
Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma: efficacy, safety and prognostic factors
Presenter: F. Tovoli, Bologna
(Abstract Authors: F. Tovoli, V. Dadduzio, S. De Lorenzo, L. Rimassa, G. Masi, M. Iavarone, F.
Marra, I. Garajova, M. P. Brizzi, B. Daniele, F. Trevisani, C. Messina, F. Di Clemente, S. Pini, G.
Cabibbo, A. Granito, M.D. Rizzato, V. Zagonel, G. Brandi, T. Pressiani, P. Federico, C. Vivaldi, I.
Bergna, C. Campani, F. Piscaglia – Bologna, Padua, Rozzano-MI, Pieve Emanuele-MI, Pisa, Milan, Florence, Parma, Orbassano-TO, Naples, Trento, Valdarno, AUSL Romagna, Palermo)
15.50÷16.50 Symposium: Liver Transplantation for HCC and non-HCC tumors 15.50-16.10 Liver Transplantation for HCC - Alessandro Vitale, Padua
16.10-16.30 Liver Transplantation for non HCC tumors - Carlo F.A. Sposito, Milan 16.30-16.50 Discussion
Certificata UNI EN ISO 9001:2015
16.50-17.40 Selected Oral Communications on Liver Failure, Hepatobiliary Surgery &
Transplantation
Chairpersons: Salvatore Petta, Palermo - Alessio Aghemo, Rozzano (MI) - Mario Masarone, Salerno - Sara Montagnese, Padua - Francesca Romana Ponziani, Rome - Francesco Paolo Russo, Padua
Regorafenib improves survival after sorafenib in patients with recurrent HCC after liver transplantation
Presenter: M. Iavarone, Milan
(Abstract Authors: M. Iavarone, F. Invernizzi, T. Ivanics, S. Mazza, C. Zavaglia, M. Sanduzzi- Zamparelli, M. Fraile-López, C. Czauderna, G. Di Costanzo, S. Bhoori, M. Pinter, M.A. Manini, G.
Amaddeo, A. Fernandez Yunquera, F. Piñero, M.J. Blanco Rodríguez, M. Anders, G. Aballay Soteras, G.E. Villadsen, P. Daechul Yoon, L. Cesarini, Á. Díaz-González, M.L. González-Diéguez, R. Tortora, A. Weinmann, V. Mazzaferro, M. Romero Cristóbal, G. Crespo, H. Regnault, M. De Giorgio, M. Varela, R. Prince, L. Scuddeler, M.F. Donato, M.-A. Wörns, J. Bruix, G. Sapisochin, P. Lampertico, M. Reig – Milan, Toronto-Canada, Barcelona-Spain, Oviedo-Spain, Mainz- Germany, Naples, Vienna-Austria, Bergamo, Créteil-France, Madrid-Spain, Latin American Liver Research Educational and Awareness Network-LALREAN, Jerez-Spain, Buenos Aires (Argentina), Mitre-Argentina, Aarhus-Denmark)
The best potential treatment for recurrent hepatocellular carcinoma after surgery: a machine learning predictive model for treatment allocation based on an Italian multicentric database
Presenter: S. Famularo, Rozzano-MI
(Abstract Authors: S. Famularo, M. Donadon, F. Cipriani, F. Fazio, F. Ardito, F. Carissimi, M.
Iaria, P. Perri, S. Conci, N. Pontarolo, Q. Lai, G. La Barba, S. Patauner, S. Molfino, P. Germani, A.
Manzoni, E. Pinotti, M. Zanello, L. Fumagalli, C. Ferrari, M. Romano, A. Delvecchio, D. P.
Bernasconi, M.G. Valsecchi, A. Antonucci, R. Memeo, G. Zanus, G. Griseri, M. Chiarelli, E.
Jovine, M. Zago, G. Zimmitti, P. Tarchi, G.L. Baiocchi, A. Frena, G. Ercolani, M. Rossi, M. Maestri, A. Ruzzenente, G.L. Grazi, R. Dalla Valle, F. Romano, F. Giuliante, A. Ferrero, L. Aldrighetti, G.
Torzilli and HE.RC.O.LE.S. Group – Rozzano-MI, Milan, Turin, Rome, Parma, Verona, Pavia, Forlì, Bolzano, Brescia, Trieste, Bergamo, Bologna, Lecco, Savona, Padua, Treviso, Bari, Monza) Pregnancy after liver transplantation: a survey from Italian liver transplants centres Presenter: S.S. Sciarrone, Padua
(Abstract Authors: S.S. Sciarrone, A. Ferrarese, S. Volpato, M.F. Donato, F. Invernizzi, L.
Trespidi, I.G. Ramezzana, A.W. Avolio, E. Nure, M.M. Pascale, S. Fagiuoli, L. Pasulo, M. Merli, L.
Lapenna, P. Toniutto, I. Lenci, R. Di Donato, N. De Maria, E. Villa, A. Galeota Lanza, S. Marenco, S. Bhoori, L. Mameli, U. Cillo, P. Boccagni, F.P. Russo, P. Bo, E. Cosmi, P. Burra - Padua, Cittadella-PD, Milan, Rome, Bergamo, Udine, Bologna, Modena, Naples, Genova, Cagliari) Liver transplant recipients with Covid-19: results from an Italian multicenter cohort Presenter: C. Mazzarelli, Milan
(Abstract Authors: C. Mazzarelli, R. Viganò, G. Perricone, M. Merli, L. Pasulo, F. Invernizzi, S.
Bhoori, M.C. Morelli, D. Patrono, S. Di Sandro, P. Cortesi, D. Angrisani, S. De Nicola, M. Vangeli, L.S. Belli – Milan, Bergamo, Bologna, Turin, Modena, Monza)
Certificata UNI EN ISO 9001:2015
17.40-18.00 Wrap-Up Session: The Best of AISF 2021 Marco Marzioni, Ancona
18.00-19.00 General Assembly II
19.00-19.30 Up to date Lecture on Specific Topics [No ECM]
Update on long term results in liver transplantation Riccardo Volpes, Palermo
Certificata UNI EN ISO 9001:2015
53
rdAISF Virtual Annual Meeting
March 3rd-4th-5th, 2021
Poster Session
N. 1 Tenofovir Alafenamide improves proximal tubular markers in CHB patients long-term treated with Tenofovir Disoproxil Fumarate: a real-life study based on the EASL switching criteria
A. Loglio, M. Viganò, M. Borghi, C. Gentile, F. Facchetti, D. Sambarino1, R. Perbellini, R. Soffredini, S.C.
Uceda Renteria, M.G. Rumi, P. Lampertico – Milan
N. 2 Non-invasive tests to predict liver-related events in a single-center cohort of 486 HCV cirrhotic patients treated with DAA
E. Degasperi, R. D’Ambrosio, I. Fanetti, R. Perbellini, M.P. Anolli, M. Borghi, R. Soffredini, P. Lampertico Milan
N. 3 Incidence of liver-related events in 647 HCV cirrhotics treated with DAA: a 5-year single center study R. D’Ambrosio, E. Degasperi, M.P. Anolli, I. Fanetti, M. Borghi, R. Soffredini, M. Iavarone, G. Tosetti, R.
Perbellini, A. Sangiovanni, P. Lampertico – Milan
N. 4 Coagulation balance and liver damage in non-cirrhotic patients with chronic hepatitis C after eradication by Direct-acting Antiviral Agents (DAAs)
G. Sigon, R. D'Ambrosio, M.G. Clerici, G. Pisano, V. Chantarangkul, R. Sollazzi, A. Cespiati, F. Iuculano, R. Lombardi, F. Peyvandi, P. Lampertico, S. Fargion, A. Tripodi, A.L. Fracanzani – Milan
N. 5 New onset steatosis but not persistent steatosis prevents hepatic fibrosis improvement after viral eradication by direct-acting antiviral therapy (DAAs) in patients with chronic hepatitis C: evaluation by controlled attenuation parameter (CAP) and liver stiffness measurement LSM
A. Cespiati, S. Petta, R. Lombardi, V. Di Marco, V. Calvaruso, C. Bertelli, G. Pisano, E. Fatta, G. Sigon, F.
Iuculano, L. Crapanzano, G. Gibilaro, P. Francione, A. Craxì, S. Fargion, A.L. Fracanzani - Milan, Palermo
N. 6 The “CASERTA MODEL”: Caserta HCV Free Hospital
V. Messina, A. Petruzziello, E. Tripaldelli, T. Squeglia, A. del Prete, P. Maggi, N. Coppola - Caserta, Naples
N. 7 Excellent long-term virological and clinical response in HDV compensated cirrhotics treated with high dose Bulevirtide beyond 2.5 years: a case series
A. Loglio, P. Ferenci, S.C. Uceda Renteria, H. Holzmann, M. Borghi, R. Perbellini, A. Rimondi, E.
Trombetta, S. Giovanelli, L. Porretti, D. Prati, F. Ceriotti, P. Lampertico - Milan, Vienna (Austria)
N. 8 A new model of care involving General Practitioners for HCV elimination in patients with mild liver disease: the experience of Pordenone (Friuli Venezia Giulia)
E. Garlatti Costa, G. Marcassa, G. Lucchini, A. Berto, R. De Rosa, M. Tonizzo – Pordenone
N. 9 A multimedia multilanguage web-based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy
L. Frazzoni, U. Sikandar, G. Mazzella, L. Fuccio, F. Bazzoli, S. Brillanti, F. Azzaroli - Bologna, Siena
Certificata UNI EN ISO 9001:2015
N. 10 Long-term efficacy and safety of obeticholic acid in patients with PBC from the POISE trial grouped biochemically by risk of disease progression
C. L. Bowlus, M. Trauner, A. Liberman, E. Malecha, L. MacConell, A. E. Kremer, F. Nevens, A. Floreani - Sacramento (CA, USA), Vienna (Austria), San Diego (CA, USA), Erlangen (Germany), Leuven (Belgium), Padua
N. 11 Epidemiological and clinical profile of 302 patients with primary biliary cholangitis in Piedmont and Liguria
C. De Benedittis, S. Labanca, A. Picciotto, A. Morgando, E. Vanni, D. Azzolina, M.G. Cittone, M. Pirisi, C.
Rigamonti - Novara, Genua, Turin
N. 12 Pattern of progression of intrahepatic cholangiocarcinoma impacts on survival: implications for second-line trials
F. Tovoli, I. Garajovà, M. Iavarone, P. Federico, F. Gelsomino, A. Granito, B. Daniele, A. Forgione, F.
Piscaglia - Bologna, Parma, Milan, Naples, Modena
N. 13 Metabolic reprogramming and mitochondrial dysfunction in HepG2 cells as potential drivers of AIP pathophysiology
M. Longo, M. Meroni, E. Paolini, M.D. Cappellini, I. Motta, A.L. Fracanzani, E. Di Pierro, P. Dongiovanni Milan
N. 14 Whole exome sequencing for the diagnosis of rare genetic conditions in patients with unexplained liver disease and complex clinical presentation
S. Pelusi, F. Malvestiti, G. Baselli, C. Bianco, C. Santaniello, L. Santoro, G. Soardo, R. D’Ambrosio, W.
Barcellini, M. Miozzo, D. Prati, L. Valenti - Milan, Udine
N. 15 EILF-Italian migrants study: an HCV and HBV micro elimination pilot project G. Colucci, S. Uceda Renteria, G. Lunghi, F. Ceriotti, E. Sguazzini, S. Spalenza, C. Regazzo, S. Scotti, E.
Renesto, A. Zucchetti, C. Paratore, P. Lampertico, M. Colombo - Milan, Geneve (Switzerland)
N. 16 Hepatocellular liver injury in hospitalized patients affected by COVID-19: different factors at different time points
M. Leo, A. Galante, A. Pagnamenta, F.R. Ponziani, A. Gasbarrini, A. De Gottardi – Lugano (Switzerland), Rome, Bellinzona (Switzerland)
N. 17 High prevalence of multiple drug resistant bacterial infections in patients with pyogenic liver abscesses following loco regional therapy for liver cancer
F. Colapietro, C. Masetti, N. Pugliese, I. Bianchi, D. Poretti, V. Pedicini, A. Lleo, R. Ceriani, A. Aghemo Rozzano (Milan), Pieve Emanuele (Milan)
N. 18 The Fibrosis-4 index is associated with Intensive Care Unit (ICU) admission in middle-aged patients with COVID-19
E. Biliotti, P. Piselli, U. Visco Comandini, R. Lionetti, C. Taibi, L. Vincenzi, S. Al Moghazi, A. Antinori, E.
Caraffa, C. Cimaglia, L. Marchioni, A. Mariano, I. Mastrorosa, S. Mosti, A. Navarra, E. Nicastri, F.
Palmieri, E. Girardi, G. D’Offizi and ReCOVeRI Study Group – Rome
N. 19 High levels of transaminases at admission predict a severe disease course in COVID-19 hospitalized patients
F. Pelizzaro, M.P. Kitenge, F. Maran, E. Cocconcelli, E. Balestro, P. Spagnolo, A. Cattelan, F. Farinati Padua
Certificata UNI EN ISO 9001:2015
N. 20 Pilot screening of HBV and HCV prevalence in at risk populations due to geographical origin and conditions of socio-economic distress
S. Lorini, L. Gragnani, S. Marri, F. Madia, M. Monti, C. Stasi, L. Petraccia, M. Bamoshmoosh, A.L. Zignego Florence, Sana'a (Yemen)
N. 21 Correlation of the transaminases alteration with the clinical severity of patients with COVID- 19: a meta-analysis of the first global outbreak
L. Miele, M. Dajko, G. Marrone, A. De Magistris, M. Biolato, A. Liguori, G.L. Rapaccini, G. Gasbarrini, A.
Grieco – Rome
N. 22 Eating habits in patients affected by metabolic syndrome and liver disease (hepatitis, cirrhosis and liver transplant)
L. Brodosi, D. Mita, G. Simonetti, G. Vitale, A. Gentile, M. Genovese, G. Marchesini, M.C. Morelli, L.
Pironi – Bologna
N. 23 Thrombocytopenia in chronic liver disease: the analysis of Italian administrative healthcare data by Fondazione RES
L. Dondi, G. Ronconi, S. Calabria, C. Piccinni, A. Pedrini, I. Esposito, N. Caporaso, U. Vespasiani Gentilucci, A. Iacobellis, N. Martini - Casalecchio di Reno (Bologna), Rome, Naples, San Giovanni Rotondo (Foggia)
N. 24 A challenging case of chronic haemolisys in liver cirrhosis: spur cell anemia
M. Bevilacqua, G. Marchi, F. Dima, R. Stupia, V. Paon, D. Ieluzzi, A. Dalbeni, D. Girelli, D. Sacerdoti – Verona
N. 25 Psychological profiles and risk of relapse in cirrhosis due to alcohol abuse
A. Galeota Lanza, G. Mazzarone, V.G.M. Moreas, A. Cangiano, F. Giordano, G. Aragiusto, G. Arenga, L.
Campanella, A. Ceriello, D. Ferraro, C. Migliaccio, D. Pisaniello, I. Esposito, F. Picciotto, G. Di Costanzo, C. Chierego, C. Esposito, G. Vennarecci – Naples
N. 26 NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease
S. Grimaudo, P. Dongiovanni, J. Pihlajamäki, M. Eslam, H. Yki-Järvinen, R.M. Pipitone, G. Baselli, C.
Cammà, V. Di Marco, M. Longo, G. Pennisi, D. Prati, R. Zito, A.L. Fracanzani, A. Craxì, J. George, S.
Romeo, L. Valenti#, S. Petta# - Palermo, Milan, Kuopio (Finland), Westmead (NSW, Australia), Helsinki (Finland), Gothenburg (Sweden)
N. 27 The role of variant rs17618244 of KLB gene in MAFLD-related fibrosis
N. Panera, M. Meroni, M. Longo, A. Crudele, L. Valenti, E. Bellacchio, L. Miele, V. D’Oria, E. Paolini, M.
Maggioni, A.L. Fracanzani, A. Alisi, P. Dongiovanni - Rome, Milan
N. 28 Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non- invasive markers of fibrosis: results of a post hoc analysis from the interim analysis of the REGENERATE study
R. Loomba, V. Ratziu, Q. M. Anstee, S. Harrison, A.J. Sanyal, M. Rinella, Z. Y. Younossi, Z. Goodman, P.
Bedossa, R. Shringarpure, H. Zhou, M. Noureddin, E. Bugianesi - San Diego (CA, USA), Paris (France), Newcastle upon Tyne (United Kingdom), San Antonio (TX, USA), Richmond (VA, USA), Chicago (IL, USA), Falls Church (VA, USA), Los Angeles (CA, USA), Turin
Certificata UNI EN ISO 9001:2015
N. 29 Rare and common ATG7 variants predispose to severe fatty liver disease
G. Baselli, S. Pelusi, E. Ciociola, P. Dongiovanni, M. Maggioni, F. Tavaglione, C. Bianco, R.M. Mancina, L. Santoro, S. Petta, L. Miele, U. Vespasiani Gentilucci, A. Federico, E. Bugianesi, A.L. Fracanzani, H.
Reeves, G. Soardo, M. Miozzo, EPIDEMIC study investigators, D. Prati, S. Romeo, L. Valenti - Milan, Gothenburg (Sweden), Rome, Udine, Palermo, Naples, Turin, Newcastle upon Tyne (UK), Catanzaro
N. 30 A cholestatic pattern predicts liver outcomes in patients with nonalcoholic fatty liver disease G. Pennisi, R. M. Pipitone, S. Grimaudo, F. Spatola, V. Di Martino, C. Cammà, V. Di Marco, A. Craxì, S.
Petta – Palermo
N. 31 TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models
M. Longo, M. Meroni, V. Erconi, F. Carli, C. Macchi, D. Ronchi, S. Sabatini, E. Paolini, E.R. De Caro, A.
Alisi, L. Miele, G. Soardo, G.P. Comi, L. Valenti, M. Ruscica, A.L. Fracanzani, A. Gastaldelli, P.
Dongiovanni - Milan, Pisa, Rome, Trieste
N. 32 Increased serum ferritin levels predict long-term mortality in patients with NAFLD A. Armandi, R. Younes, G.P. Caviglia, S. Petta, L. Miele, C. Rosso, G. Pennisi, P. Francione, A. Liguori, O.
Govaere, A.L. Fracanzani, M. Eslam, L. Valenti, J. George, Q.M. Anstee, E. Bugianesi - Turin, Ingelheim (Germany), Palermo, Rome, Milan, Newcastle upon Tyne (United Kingdom), Westmead (NSW, Australia)
N. 33 MicroCT evaluation of low-density segmented volume in II, IV and VII-week MCD rats M. Filibian, L.G. Di Pasqua, C. Berardo, M. Cagna, M. Vairetti, A. Ferrigno – Pavia
N. 34 Angiopoietin-2 associated with NASH in paediatric NAFLD
N. Panera, M. Manco, A. Crudele, M.R. Braghini, M. Bianchi, D. Comparcola, R. De Vito, G. Maggiore, A. Alisi – Rome
N. 35 The I148M PNPLA3 variant mitigates Niacin beneficial effects: how the genetic screening in NAFLD patients gains value
E. Paolini, M. Longo, M. Meroni, G. Malaspina, E.R. De Caro, A. Cespiati, R. Lombardi, A.L. Fracanzani, P. Dongiovanni – Milan
N. 36 No impact of the 2020 COVID-19 lockdown on hospitalization rates for alcoholic liver disease in a large tertiary hospital in Milan
C. Masetti, F. Colapietro, N. Pugliese, F. De Fazio, A. Voza, I Bianchi, R. Ceriani, A. Lleo, A. Aghemo - Rozzano (Milan), Pieve Emanuele (Milan)
N. 37 General Practitioner databaSe NAFLD (GPS-NAFLD) study: Italian regional variability of the NAFLD prevalence rate
L. Miele, I. Grattagliano, F. Lapi, M. Dajko, A. Liguori, A. De Magistris, C. Napodano, A. Rossi, G.
Rapaccini, A. Gasbarrini, C. Cricelli, A. Grieco – Rome, Florence
N. 38 Oleuropein prevents liver damage in NAFL mice by modulating copper-catalyzed dicarbonyl stress S.J. Santini, I. Settepanella, C. Balsano - L’Aquila, Rome
Certificata UNI EN ISO 9001:2015
N. 39 Screening and detecting significant liver fibrosis in patients with NAFLD: a practical approach using non-invasive tests
G. Alterini, P. Sacco, C. Formichi, C. Ciuoli, E. Ceccarelli, S. Gonnelli, L. Volterrani, M.G. Castagna, F.
Dotta, S. Brillanti – Siena
N. 40 Multimorbidity and polypharmacotherapy in Italian primary care patients with NAFLD: General Practitioner databaSe NAFLD (GPS-NAFLD) Study
L. Miele, C. Cricelli, F. Lapi, I. Grattagliano, M. Dajko, A. Liguori, A. De Magistris, C. Napodano, G.
Marrone, M. Biolato, A. Rossi, G. Rapaccini, A. Grieco, A. Gasbarrini – Rome, Florence
N. 41 The PSRC1 rs599839 A>G variant disentangles the risk of coronary artery disease and hepatocellular carcinoma in Italian NAFLD patients
M. Meroni, M. Longo, E. Paolini, E.R. De Caro, A. Alisi, L. Miele, G. Soardo, L. Valenti, A.L. Fracanzani, P. Dongiovanni - Milan, Rome, Trieste
N. 42 Prognostic role of platelets-to lymphocytes ratio (PLR) and neutrophils-to-lymphocytes ratio (NLR) in hepatocellular carcinoma patients
F. Pelizzaro, A. Sartori, A. Imondi, B. Penzo, A. Vitale, F. Trevisani, F. Farinati on behalf of the Italian Liver Cancer (ITA.LI.CA) group – Padua, Bologna
N. 43 Is first- and second-line immunotherapy sequence the optimal strategy for unresectable hepatocellular carcinoma?
C. Celsa, G. Cabibbo, S. Battaglia, M. Enea, G.E.M. Rizzo, A. Busacca, C. Stornello, P. Giuffrida, A. Craxì, C. Cammà - Palermo
N. 44 The protease-inhibitor serpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma
M. Correnti, A. Cappon, M. Pastore, B. Piombanti, G. Lori, D. VPN Oliveira, P. Munoz-Garrido, M.
Lewinska, J.B. Andersen, C. Coulouarn, L. Sulpice, G. Cavalloni, S. Quarta, A. Biasiolo, M. Fassan, P.
Invernizzi, G. Torzilli, F. Marra, P. Pontisso, C. Raggi – Rozzano (Milan), Padua, Florence, Copenhagen (Denmark), Rennes (France), Turin, Monza
N. 45 Perfusion analysis with dynamic contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma: a pilot study of a novel parameter aiming to improve the detection of wash-out
L. Mulazzani, A. Forgione, C. Di Bonaventura, E. Terzi, L. Gramantieri, A. Lyshchik, F. Piscaglia - Bologna, Philadelphia (PA, US)
N. 46 Progression-free survival is a robust surrogate endpoint of overall survival in immunotherapy trials of hepatocellular carcinoma
C. Celsa, G. Cabibbo, M. Enea, S. Battaglia, G.E.M. Rizzo, A. Busacca, D. Matranga, M. Attanasio, M.
Reig, A. Craxì, C. Cammà - Palermo, Barcelona (Spain)
N. 47 Hepatocellular carcinoma prognostic scores: a 10 years experience
M. Campigotto, M. Giuffrè, A. Colombo, A. Visintin, M. Budel, A. Aversano, C.A.M. Cavalli, A. Piccin, R.
Sigon, F. Masutti, C. Abazia, F. Tinè, L.S. Crocè – Trieste
N. 48 Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma. A diagnostic test accuracy Cochrane review
A. Colli, T. Nadarevic, D. Miletic, V. Giljaca, M. Fraquelli, D. Štimac, G. Casazza - Milan, Rijeka (Croatia), Birmingham (UK)
Certificata UNI EN ISO 9001:2015
N. 49 A mitochondrial role of RuvBL1 ATPase in the regulation of HCC cell metabolism
I. Simeone, A. Guida, M. Materozzi, S. Polvani, D. Bani, M. Parri, E. Ceni, A. Galli, T. Mello - Florence, Siena
N. 50 Fatty Acids regulate the biology of cholangiocarcinoma cells
G. Lori, C. Raggi, B. Piombanti, M. Pastore, R. Booijnk, E. Rovida, J.B. Andersen, M. Lewinska, F. Marra Florence, Twente (The Netherlands), Copenhagen (Denmark)
N. 51 AFP at transplant is associated with a higher risk of HCC recurrence after liver transplantation for patients meeting Milano criteria
B. Magro, D. Pinelli, M. De Giorgio, A. Ghirardi, B. Giuseppe, L. Del Prete, M. Colledan, S. Fagiuoli Bergamo
N. 52 Increased platelet aggregation in patients with cirrhosis and hepatocellular carcinoma: a new potential therapeutic target?
A. Zanetto, E. Campello, S. Shalaby, M. Gambato, A. Vitale, U. Cillo, F. Farinati, F.P. Russo, P. Burra, P.
Simioni, M. Senzolo – Padua
N. 53 Circulating microRNA-23b-3p and tissue microRNA-193a-3p as promising molecular biomarkers in human hepatocellular carcinoma
I. Grossi, G. Baiocchi, S. Molfino, N. Portolani, M. Ferracin, P. Guerriero, M. Negrini, A. Salvi, G. De Petro Brescia, Bologna, Ferrara
N. 54 Copper chelation as a new treatment strategy to counteract hepatocellular carcinoma S.J. Santini, M.R. Braghini, A. Alisi, C. Balsano - L’Aquila, Rome
N. 55 Abnormal glycosphingolipid patterns in human cholangiocarcinoma stem-like subsets A. Mannini, C. Raggi, M. Correnti, E. Rovida, M. Aureli, E.V. Carsana, B. Piombanti, M. Pastore, J.
Andersen, C. Coulouarn, F. Marra - Milan, Florence, Copenhagen (Denmark), Rennes (France)
N. 56 Modeling hepatocellular carcinoma cells dynamics by serological and imaging biomarkers in patients with response to sorafenib and/or regorafenib
P. Colombatto, C.O. Demirtas, G. Ricco, L. Civitano, P. Boraschi, P. Scalise, D. Cavallone, F. Oliveri, V. Romagnoli, P. Bleve, B. Coco, A. Salvati, L. Urbani, F. Bonino, M.R. Brunetto– Pisa, Istanbul (Turkey)
N. 57 Circulating prostaglandin E2: a novel potential prognostic biomarker in patients with hepatocellular carcinoma
F. Pelizzaro, M. P. Kitenge, R. Cardin, B. Penzo, A. Ponzoni, U. Cillo, A. Vitale, G Businello, G. Munari, M.
Fassan, F. Farinati – Padua
N. 58 Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma C. Campani, M. Capone, F. Liotta, U. Arena, C. Di Bonaventura, S. Colagrande, F. Annunziato, F. Marra Florence
Certificata UNI EN ISO 9001:2015
N. 59 Comparing surgery versus sorafenib in advanced hepatocellular carcinoma: an Italian weighted study
S. Famularo, M. Donadon, F. Cipriani, F. Giuliante, A. Ferrero, S. Molfino, R. Dalla Valle, M.
Chiarelli, M. Maestri, E. Jovine, G.L. Grazi, A. Ruzzenente, R. Memeo, M. Crespi, A. Antonucci, D.P.
Bernasconi, F. Romano, G. Griseri, L. Aldrighetti, G. Torzilli, F. Trevisani on behalf of ITA.LI.CA. Group and HE.RC.O.LE.S. Group – Milan, Rozzano (Milan), Rome, Turin, Brescia, Parma, Lecco, Pavia, Bologna, Verona, Bari, Monza, Savona
N. 60 OCA administration reduces lung matrix metalloproteinase activation following hepatic ischemia/reperfusion injury in rats
L.G. Di Pasqua, C. Berardo, G. Palladini, M. Cagna, L. Adorini, P. Richelmi, A. Ferrigno, M. Vairetti Pavia, San Diego (CA, USA)
N. 61 Treatment of CRKP infections in cirrhotic patients
S. Feldman, S. Di Cola, C. Madge, P. Vassalini, C. Borrazzo, G. Ceccarelli, M. Merli – Rome
N. 62 Risk factors for post-banding ulcer bleeding in cirrhotic patients undergoing elective esophageal varices band ligation
G. Tosetti, E. Farina, R. Caccia, E. Degasperi, M. Primignani, P. Lampertico – Milan
N. 63 The impact of a local antibiotic stewardship program: low rate of spontaneous bacterial peritonitis and bacteriascites sustained by multidrug-resistant organisms
A. Mantovani, M. Bevilacqua, A. Mazzariol, A. Azzini, E. Tacconelli, D. Sacerdoti, A. Dalbeni Verona
N. 64 Analysis of clinical course of portal vein thrombosis in cirrhosis with hepatocellular carcinoma M. Grasso, A. Vitale, E. Pizzirani, A. Zanetto, E. Gringeri, F. D'Amico, M. Gambato, U. Cillo, P. Burra, M.
Senzolo – Padua
N. 65 Ultrasound guided paracentesis: a study on reproducibility and diagnostic accuracy of a Pocket-size Ultrasound Device (PUD)
A. Costantino, S. Costa, D. Noviello, E. Farina, M. Vecchi, P. Lampertico, A. Sangiovanni, M. Fraquelli – Milan
N. 66 Liver Transplantation during the COVID-19 pandemic: a quantitative model balancing individual patient benefit against population healthcare needs
U. Cillo, A.Vitale, M.L. Volk, A.C. Frigo, P. Feltracco, A. Cattelan, G. Brancaccio, G. Feltrin, P. Angeli, P.
Burra, S. Lonardi, S. Trapani, M. Cardillo – Padua, Loma Linda (CA, USA), Rome
N. 67 Proposal of a new evidence based definition of Early Allograft Failure to identify patients who needs early retransplant and call for a prospective external validation study
A.W. Avolio, G. Moschetta, A. Contegiacomo, L. Miele, L. Teofili, G. Spoletini, S. Agnes, F. Frongillo, G.
Bianco, G. Marrone, M. Biolato, A. Grieco, A. Gasbarrini, P. Burra - Rome, Padua
N. 68 Prevalence and impact on post-transplant outcome of sarcopenia among patients with cirrhosis on waiting-list for liver transplantation: preliminary data from an Italian single center experience F. Invernizzi, M. Iavarone, S. Crespi, B. Antonelli, M. Rusalen, G. Fornoni, G. Carrafiello, G. Rossi, M.F.
Donato, P. Lampertico – Milan
Certificata UNI EN ISO 9001:2015
N. 69 Liver transplant candidates and SARS-CoV-2 infection: results from an Italian multicenter cohort G. Perricone, R. Vigano, C. Mazzarelli, G. Travi, L. Pasulo, F. Invernizzi, M.C. Morelli, D. Patrono, S. Di Sandro, P. De Simone, R. Facchetti, D. Angrisani, S. De Nicola, A. Airoldi, M. Vangeli, L.S. Belli – Milan, Bergamo, Bologna, Turin, Modena, Pisa, Monza
N. 70 COVID-19 and Solid Organ Transplantation (SOT) in Italy: a web-survey
F. Galiandro, S. Agnes, F. Giovinazzo, A. Vitale, R. Romagnoli, C. Amarelli, U. Maggiore, P. Burra, U.
Boggi, A.W. Avolio - Rome, Padua, Turin, Naples, Parma, Pisa
N. 71 Liver Transplant in Patient with Breast Cancer Liver Metastasis and Hepatic Failure
V. Giannelli, R. Meniconi, N. Guglielmo, M. Colasanti, C. D'Ambrosio, R. Cianni, E. Cortesi, G.B. Levi Sandri, A.M. Pellicelli, G.M. Ettorre – Rome
N. 72 Liver stiffness in the early post-liver transplant phase as a marker of acute allograft rejection A. Liguori, M. Pascale, M. Biolato, G. Marrone, L. Miele, R. Gaspari, A.W. Avolio, S. Agnes, A. Grieco – Rome